This month marks the renewal period for Pfizer’s contract research organizations’ Icon and Parexel, and while revenues have been declining, analysts believe the pharma giant will renew with both companies.
The UK’s BioCity in Nottingham is adding a £30m ($47m) facility to house life science start-ups including CROs. The site will also become a hunting ground for a soon-to-launch venture capital fund which will invest in the SME tenants.
CRO Parexel’s staffing numbers took center stage during its earnings call Thursday as the company re-iterated plans to lay off as many as 850 employees – mostly in higher-cost countries -- to increase its margins.
A new four-year research project involving a consortium of government, non-profit and other large biopharma partners is aiming to create a set of measures that can be used in clinical trials to determine which ASD (autism spectrum disorder) treatments...